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Summary
Objectives: In full-thickness articular defects, ﬁbroblast growth factor-2 (FGF-2) participates in the chondrogenic repair response which occurs
in a defect-size dependent manner. Here we demonstrate that FGF-2 plays a critical role in the proliferation of pre-chondrogenic mesenchymal
cells during chondrogenic induction.
Methods: Three-millimeter- or 5-mm-diameter cylindrical defects were created in the femoral trochlea of the rabbit knee. The defects received
sterile saline or FGF-2 (50 pg/h) via an osmotic pump for the initial 2 weeks. We assessed the proliferative capacity of undifferentiated
mesenchymal cells in the reparative tissue with the anti-proliferating cell nuclear antigen (PCNA) monoclonal antibody. Using a total of 180
rabbits, we performed three sets of experiments.
Results: In the 3-mm-diameter defects, undifferentiated mesenchymal cells spontaneously initiated chondrogenic differentiation within 2
weeks, resulting in the regeneration of surfacing articular cartilage concomitantly with the repair of subchondral bone. No evidence of
chondrogenesis was seen in the 5-mm-diameter defects, whereas application of FGF-2 promoted successful regeneration of articular
cartilage. In the 3-mm-diameter defects and in the FGF-2-treated 5-mm defects, PCNA immunoreactivity was widely detected in
undifferentiated cells in the reparative tissue at 1 and 2 weeks after creation of the defects. In contrast, in the 5-mm-diameter defects without
FGF-2 treatment, the PCNA-positive cells were found at a signiﬁcantly lower incidence.
Conclusions: Active expansion of undifferentiated cell population mediated by FGF-2 is required to initiate and support a chondrogenic repair
response in full-thickness defects of articular cartilage. Endogenous FGF-2 could not meet the requirements of growth signaling in the center
of larger sized defects.
 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Full-thickness defects that penetrate articular cartilage
undergo repair to end up with either ﬁbrous, or ﬁbrocarti-
laginous tissue or, to a very limited extent, hyaline cartilage.
Adult bone marrow contains mesenchymal cells that have
the potential to differentiate into the adipogenic, chondro-
genic, and osteogenic lineages1. These cells can migrate
from the underlying bone marrow into the defect cavities,
and are thought to be responsible for the sequential
reparative responses2. In an adolescent rabbit model of
defects created in the femoral trochlea, the regenerative
capacity largely depends on their size2,3. Smaller cylindrical
defects (%3 mm in diameter) spontaneously regenerate
surfacing articular cartilage concomitantly with repair of the
subchondral bone through differentiation of mesenchymal
progenitor cells. In contrast, overt chondrogenesis does not
occur in larger defects (R5 mm in diameter), but results in
the formation of ﬁbrous scar tissue. However, little is known
about how the chondrogenic repair response occurs in a
defect-size dependent manner.
The sequence of events during chondrogenesis is re-
gulated by various growth and differentiation factors such
as ﬁbroblast growth factor (FGF), insulin-like growth factor-l
(IGF-I), transforming growth factor-b (TGF-b), and members
of bone morphogenetic protein (BMP) family4. Among them,
FGF signaling has been suggested to play a role in support
of the proliferation of mesenchymal progenitor cells5e7. We
previously reported that the local administration of FGF-2
facilitated the regenerative repair of articular cartilage to
overcome the size-limitation of the regenerative capacity of
cartilage in a 5-mm-diameter full-thickness articular carti-
lage defect of the rabbit knee3,8. In 5-mm-diameter defects,
the administration of FGF-2 (50 pg/h for 2 weeks) in the
defect cavities induced the chondrogenic repair within
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articular cartilage. On the other hand, even in 3-mm-
diameter smaller defects, spontaneous chondrogenic repair
failed to occur when the action of endogenous FGF-2 was
blocked by the administration of a neutralizing antibody
against FGF-23. Thus we hypothesized that the role of FGF-
2 was to promote proliferation of prechondrogenic mesen-
chymal cells in the defects during cartilage induction. Here
we extensively studied the proliferative response of un-
differentiated mesenchymal cells during repair of full-
thickness defects of articular cartilage using a monoclonal
antibody against proliferating cell nuclear antigen (PCNA)
for gaining insight into the role of FGF-2 actions for the
defect-size dependent induction of chondrogenic repair.
Materials and methods
CREATION OF FULL-THICKNESS DEFECTS OF ARTICULAR
CARTILAGE
Small full-thickness defects (3 mm in diameter; 4 mm in
depth) were created in the weight-bearing area of the
femoral trochlea of 20 adolescent Japanese white rabbits
(weighing 3.0 3.4 kg; purchased from KBT Oriental Co., Ltd,
Tosu, Japan) by an electric drill with a 3-mm-diameter drill-
bit under anesthetization by sodium pentobarbital (30 mg/
kg bodyweight intravenously), as described previously3.
Larger full-thickness defects (5 mm in diameter; 4 mm in
depth) were similarly created with a 5-mm-diameter drill-bit
in 40 rabbits. All animals were allowed to walk freely without
any splintage. Animal care and experimental procedures
were conducted in accordance with institutional guidelines
(http://card.medic.kumamoto-u.ac.jp/card/japanese/kisoku/
kisoku.html).
ADMINISTRATION OF FGF-2
The animals were ﬁtted with an osmotic pump (model
2002; Alzet, Palo Alto, CA) connected to silastic medical
grade tubing (0.75 mm internal-diameter/1.45 mm outer-
diameter). A length of the tubing about 5 mm was
introduced into the articular knee cavity through the articular
capsule in order to administer agents in the defect cavity.
The osmotic pump was placed subcutaneously in the hind
region of the leg, and the articular capsule and skin were
closed independently3. For 20 animals that had a 5-mm-
diameter defect, the osmotic pump had been previously
ﬁlled with 200 ml of sterile saline containing human
recombinant FGF-2 (Takeda Chemical Industries, Osaka,
Japan; 0.1 mg/ml). The pump had a nominal pumping rate of
0.5 ml/h for a 2-week period. The other 20 animals that had
a 5-mm-diameter defect and 20 animals that had a 3-mm-
diameter defect received sterile saline alone with the same
osmotic pump system. For the subsequent histochemical
and immunohistochemical analyses, the animals were
sacriﬁced at 1, 2, 4, or 8 weeks after creation of the
defects. Three sets of experiments were performed by
using a total of 180 rabbits, and reproducibly yielded the
similar results.
HISTOCHEMICAL ANALYSES
Five animals in each group were sacriﬁced with an
overdose of sodium pentobarbital at the indicated times.
The distal portion of each femur was removed, ﬁxed in 4%
paraformaldehyde at room temperature for 1 h, decalciﬁedwith 10% ethylenediamine tetraacetic acid (EDTA) in
10 mM phosphate buffer ( pH 7.4) for 3 weeks, and then
embedded in parafﬁn for subsequent histological analysis.
Sections (5 mm thick) were cut in the transverse plane, and
stained with hematoxylin and eosin or with safranin-O.
IMMUNOHISTOCHEMICAL ANALYSES
The presence of type I and type II collagen in the repar-
ative tissues was examined immunohistochemically using a
mouse monoclonal antibody against human type I and type
II collagen (Fuji Chemical, Takaoka, Japan) that speciﬁcally
crossreact with rabbit type I and type II collagen, re-
spectively9. The parafﬁn sections were deparafﬁnized and
hydrated. Endogenous peroxidase activity was blocked with
0.5% hydrogen peroxide in methanol and washed in 0.1%
bovine serum albumin (BSA) in Tris-buffered saline (TBS).
The sections were then treated with 500 U/ml testicular
hyaluronidase (Sigma Chemical Co., St Louis, MO, USA).
Non-speciﬁc staining was reduced by incubation with horse
serum. The sections were incubated with the antibody
against type I collagen (dilution 1:100) or with the antibody
against type II collagen (dilution 1:100) overnight at 4(C.
Antibody binding was visualized by using a Vectastain
avidinebiotineperoxidase complex (ABC) kit (Vector Lab-
oratories, Burlingame, CA) in combination with diamino-
benzidine (DAB) solution according to the manufacturer’s
instructions. The sections were counterstained with hema-
toxylin.
For proteoglycan immunostaining, the mouse monoclonal
antibodies 2B6, 3B3, and 5D4 (Seikagaku Kogyo, Tokyo,
Japan) were used to detect the localization of chondroitin-4-
sulfate, chondroitin-6-sulfate, and keratan sulfate, respec-
tively. Sections were deparafﬁnized and hydrated. The
sections were treated with 5 U/ml chondroitinase ABC
(Seikagaku Kogyo, Tokyo, Japan) in 0.1 M Triseacetate
buffer pH 8.0 at 37(C for 60 min. Endogenous peroxidase
activity was blocked by 0.5% hydrogen peroxidase in
methanol. The sections were washed in 0.1% BSA in
TBS and non-speciﬁc staining was reduced by incubation
with 1.3% horse serum. The sections were incubated with a
monoclonal antibody 2B6, 3B3, or 5D4 (diluted 1:50)
overnight at 4(C. For visualization of antibody binding, a
subsequent reaction was performed as described above.
The sections were counterstained with hematoxylin.
To assess the presence of macrophages, vascular endo-
thelial cells, and osteoblasts in the reparative tissue, we ﬁrst
stained the sections of the femoral trochlea recovered at 1
and 2 weeks after the creation of the defects with antibodies
against CD68 (EBM11; Dakopatts, Copenhagen, Den-
mark), CD31 (JC/70A; Dakopatts, Copenhagen, Denmark)
or alkaline phosphatase (AP-59; Sigma Chemical, St Louis,
MO), respectively. For the immunostaining, the sections
were cut, deparafﬁnized, and hydrated. Endogenous perox-
idase activity was blocked by 0.5% hydrogen peroxide in
methanol. The sections were washed in 0.1% BSA in TBS.
Non-speciﬁc staining was reduced by incubation with 1.3%
horse serum. The sections were incubated with JC/70A
monoclonal antibody (dilution 1:10) at room temperature for
30 min, with EBM11 (dilution 1:50) or AP-59 (dilution 1:100)
monoclonal antibody at room temperature for 1 h. For
visualization of antibody binding, a subsequent reaction
was performed as described above. The sections were then
counterstained with methyl green. The tissue of the femoral
trochlea was included in the study as a positive control for
identiﬁcation of macrophages (osteoclasts), vascular endo-
thelial cells, and osteoblasts.
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sections were cut, deparafﬁnized, and dehydrated. Endog-
enous peroxidase activity was blocked by 0.5% hydrogen
peroxide in methanol. The sections were washed in 0.1%
BSA in TBS, and then treated with 500 U/ml testicular
hyaluronidase (Sigma Chemical, St Louis, MO)10. Non-
speciﬁc staining was reduced by incubation with 1.3%
horse serum. The sections were incubated with a mono-
clonal antibody against PCNA (clone PC10; Dakopatts,
Copenhagen, Denmark), diluted 1:400 with PBS, at room
temperature for 2 h. For visualization of antibody binding,
a subsequent reaction was performed as described above.
The sections were then counterstained with methyl green.
For the detection of PCNA, the growth plate of Japanese
white rabbits was used as a positive control11.
Sections were incubated with either horse serum or
puriﬁed non-immune mouse IgG (Sigma Chemical Co., St.
Louise, MO) instead of speciﬁc primary antibodies, and
stained as a negative control.
ESTIMATION OF CELLULARITY AND CELL PROLIFERATION
IN THE DEFECT CAVITIES
The packing cell density of the reparative tissue in the
defects was examined by the methods of Gallay et al. using
the sections stained with hematoxylin and eosin12. A
section of the defects was divided into 12 square areas, 1
mm!1 mm, in the 3-mm-diameter defects and into 20
square areas of the same size in the 5-mm-diameter
defects. We enrolled all the areas in the defects at 1 week,
while the peripheral and deeper four areas that were
completely ﬁlled with newly formed bone were excluded at 2
weeks (Fig. 1). Two ﬁelds were selected at a magniﬁcation
of !200 in each of sampling areas, and all nuclei except
those of endothelial cells in capillaries and inﬂammatory
cells were counted. The cell density in the defects was
calculated from the mean number of cell nuclei that was
divided by the size of area. Three sections from each
parafﬁn block were used to calculate the average cell
density for one animal. The mean and standard deviation(SD) of cell densities were calculated for ﬁve animals in
each experimental group.
The PCNA-positive cells were counted according to the
method of Aizawa et al. using the sections stained by PCNA
antibodies11. Sampling square areas (1 mm!1 mm) were
determined similarly as described above. Five ﬁelds were
selected at a magniﬁcation of!400 in each sampling area,
and the positive and negative mesenchymal cells were
counted in each ﬁeld. The incidence of PCNA-positive cells
was calculated for the peripheral and central region of the
defect, respectively. The peripheral region of defects was
deﬁned as the areas that were adjacent to the persisting
marrow trabeculae or that were partially invaded by newly
formed woven bone. As shown in Fig. 1, at 1 week, the
peripheral region contained nine areas in the 3-mm defects
and 11 areas in the 5-mm defects. At 2 weeks, six areas of
the 3-mm defects and nine areas of the 5-mm defects were
regarded as the peripheral region. The other areas in each
defect were deﬁned as the central region. The measure-
ments were carried out using three sections from each
parafﬁn block for one animal. The results were expressed
as the mean and SD for ﬁve animals in each experimental
group.
Sections were examined in a blinded manner by the
evaluators not informed on the group assignment. For
microscopic analysis, an Axioskop microscope equipped
with MC10 photomicrographic attachment (Carl Zeiss,
Germany) was used. Statistical signiﬁcance was estimated
using ManneWhitney’s U test. A P value of !0.05 was
considered signiﬁcant.
Results
HISTOLOGICAL AND IMMUNOHISTOCHEMICAL OBSERVATIONS
In rabbit, full-thickness defects of articular cartilage
reproducibly take either chondrogenic or non-chondrogenic
repair pathway primarily depending on the size of the
defects2,3. In the 3-mm-diameter small defects, the defect
cavity was mostly ﬁlled with undifferentiated spindle-shaped
cells by 1 week after creation of defects [Fig. 2(A)]. At 2BA
C
A 3-mm-diameter defect at 2 weeks
A 3-mm-diameter defect at 1 week
D
A 5-mm-diameter defect at 2 weeks
A 5-mm-diameter defect at 1 week
Articular Cartilage
Subchondral Bone
Fig. 1. Schematic illustration showing sampling ﬁelds used for determining the packing cell density of the undifferentiated mesenchymal cells
and the incidence of PCNA-positive cells in the 3-mm-diameter (A, C) and 5-mm-diameter (B, D) defects. The defects at 1 week and 2 weeks
are shown in panels A and B, and panels C and D, respectively. Open squares represent the peripheral region of the defects, and shaded
squares represent the central region of the defects.
589Osteoarthritis and Cartilage Vol. 12, No. 7Fig. 2. Transverse sections of the reparative 3-mm-diameter defects treated with saline alone (A, D, G, J), 5-mm-diameter defects treated with
saline alone (B, E, H, K), and 5-mm-diameter defects treated with FGF-2 (C, F, I, L). The sections were stained with safranin-O at (AeC) 1
week, (DeF) 2 weeks, (Gel) 4 weeks, and (JeL) 8 weeks after creating the defects. Bar: 500 mm.weeks, spherical chondrocytes surrounded by extracellular
matrix stainable with safranin-O appeared in the central
region of the defect cavity [Fig. 2(D)]. Appositional repair of
subchondral bone had already been started. At 4 weeks,
the defects were occupied by cartilaginous tissue with
abundant cartilage matrix, which was actively replaced by
subchondral bone from the depths of the defects [Fig. 2(G)].
The epiphyseal structure with the resurfacing hyaline-like
cartilage was regenerated, and the original boneearticular
cartilage junction was recovered by 8 weeks [Fig. 2(J)].
In the 5-mm-diameter larger defects, by contrast, un-
differentiated spindle-shaped cells appeared at the periph-
ery of the defect, and the center of the defect was ﬁlled with
blood clot at 1 week, regardless of treatments with FGF-2
[Fig. 2(B, C)]. At 2 weeks, in the non-treated defects,
osteoblastic differentiation of cells had taken place near the
subchondral bone surface, but there was no evidence of
cartilage formation [Fig. 2(E)]. The defects were almost
ﬁlled with ﬁbrous reparative tissue even at 4 weeks afterdefect creation [Fig. 2(H)]. At 8 weeks, the subchondral
bone was almost reconstituted, but cells surfacing the
defects were mostly non-chondrocytic and the matrix was
not stained with safranin-O [Fig. 2(K)]. In the FGF-2-treated
5-mm-diameter defects, chondrogenic differentiation took
place in the periphery of the subchondral bone surface
within 2 weeks, as indicated by the appearance of spherical
cells with the safranin-O positive extracellular matrix [Fig.
2(F)]. At 4 weeks, the defects were occupied by cartilag-
inous tissue, which was replaced gradually by the apposi-
tional growth of subchondral bone from the depth [Fig. 2(I)].
At 8 weeks, well-developed cartilage covered the defects,
and the thickness of the safranin-O stained matrix had
almost recovered that of the original articular cartilage [Fig.
2(L)].
In order to further assess the character of reparative
tissue, the immunostaining for type I and type II collagens
was performed (Figs. 3 and 4). In the 3-mm-diameter-
defects, immunoreactivity to type I collagen was detected in
590 H. Mizuta et al.: Cell Proliferation in Cartilage repairFig. 3. Immunohistochemistry of type I collagen in the reparative 3-mm-diameter defects treated with saline alone (A, D), 5-mm-diameter
defects treated with saline alone (B, E), and 5-mm-diameter defects treated with FGF-2 (C, F) at 4 weeks (AeC) and at 8 weeks (DeF) after
creation of the defects. Arrowheads indicate the boundary between the pre-existing articular cartilage (on the left side) and the reparative
tissue (on the right side). The sections were counterstained with hematoxylin. Bar: 300 mm.
Fig. 4. Immunohistochemistry of type II collagen in the reparative 3-mm-diameter defects treated with saline alone (A, D), 5-mm-diameter
defects treated with saline alone (B, E), and 5-mm-diameter defects treated with FGF-2 (C, F) at 4 weeks (AeC) and at 8 weeks (DeF) after
creation of the defects. Arrowheads indicate the boundary between the pre-existing articular cartilage (on the left side) and the reparative
tissue (on the right side). The sections were counterstained with hematoxylin. Bar: 300 mm.
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cartilaginous tissues, as well as the pre-existing bony tissue
at 2 weeks after creation of defects. At 4 weeks, as
cartilaginous repair proceeded, the immunoreactivity was
seen only at the surface of the reparative tissue [Fig. 3(A)]. At
8 weeks, there was no immunoreactivity to type I collagen in
the most of the repaired articular cartilage, although the
expression of type I collagen was persisted at the superﬁcial
layer [Fig. 3(D)]. In the FGF-2-treated 5-mm-diameter
defects [Fig. 3(C, F)], a similar distribution of the type I
collagen immunoreactivity was observed in the immature
reparative tissue at superﬁcial layer of cartilage. No apparent
immunoreactivity was detected in either regenerated or
pre-existing cartilaginous tissue. Marked induction of type
I collagen was seen in the ﬁbrous repair tissue formed in the
5-mm-diameter defects without the FGF-2 treatment [Fig. 3
(B, E)]. In clear contrast, the formation of type II collagen in
cartilaginous tissues was detected by immunostaining at 2
weeks in the 3-mm-diameter defects. At 4 weeks, immuno-
reactive type II collagen was clearly detected in the
regenerating cartilaginous tissue as well as pre-existing
articular cartilage [Fig. 4(A)]. Surfacing immature reparative
tissue, which was positive for type I collagen, was negative
for type II collagen [Fig. 4]. At 8 weeks, reparative
cartilaginous tissue was indistinguishable from pre-existing
articular cartilage with regard to immunoreactivity to type II
collagen [Fig. 4(D)]. In the 5-mm-diameter defects with the
FGF-2 treatment, regenerated cartilaginous tissue markedly
expressed type II collagen to the extent comparable with pre-
existing articular cartilage [Fig. 4(C, F)]. There was no
immunoreactivity detected in ﬁbrous reparative tissue
formed in the 5-mm-diameter defects without the FGF-2
treatment [Fig. 4(B, E)].
To assess the character of extracellular matrix in the
cartilaginous reparative tissue9, immunohistochemical stud-
ies were carried out with monoclonal antibodies against
Fig. 5. Immunohistochemistry of chondroitin-4-sulfate (A, B), chondroitin-6-sulfate (C, D), and keratan sulfate (E, F) in the reparative 3-mm-
diameter defects treated with saline alone (A, C, E), 5-mm-diameter defects treated with FGF-2 (B, D, F) at 8 weeks after creation of the
defects. Arrowheads indicate the boundary between the pre-existing articular cartilage (on the left side) and the reparative tissue (on the right
side). The sections were counterstained with hematoxylin. Bar: 300 mm.
592 H. Mizuta et al.: Cell Proliferation in Cartilage repairFig. 6. Immunohistochemistry of CD68 (A, B, G, H, M, N), CD31 (C, D, I, J, O, P), and alkaline phosphatase (E, F, K, L, Q, R) in the reparative
tissues in the 3-mm-diameter defects treated with saline alone (AeF), 5-mm-diameter defects treated with saline alone (GeL), and 5-mm-
diameter defects treated with FGF-2 (MeR) at 1 weeks after creation of the defects. Panels B, F, H, L, N, and R show osteoclasts (B, H, N) and
osteoblasts (F, L, R) visualized (brown) by anti-CD68 and anti-alkaline phosphatase antibodies respectively, and used as positive controls for
conﬁrmation of the speciﬁc immunoreactivity of antibodies. Panels D, J, and P show vascular endothelial cells that were visualized by anti-
CD31 antibody in the neighboring bony tissue. The sections were counterstained with methyl green. Bar: 50 mm.chondroitin-4-sulfate, chondroitin-6-sulfate, and keratan
sulfate (Fig. 5). In the 3-mm-diameter defects at 4 and 8
weeks [Fig. 5(A, C, E)], immunoreactivities to chondroitin-4-
sulfate, chondroitin-6-sulfate, and keratan sulfate were
clearly detected in cartilaginous reparative tissues, at levels
similar to those in the pre-existing articular cartilage. In the
FGF-2-treated 5-mm-diameter defects, these glycosamino-
glycans in cartilage proteoglycans were detected in
regenerated chondrocytes and the surrounding matrix at 4
and 8 weeks [Fig. 5(B, D, F)].
LOCALIZATION OF PCNA-POSITIVE CELLS IN REPARATIVE TISSUE
To assess the presence of macrophages, vascular
endothelial cells, and osteoblasts in the reparative tissue,
we ﬁrst stained the sections of the femoral trochlea re-
covered at 1 week after the creation of the defects with
antibodies against CD68, CD31 or alkaline phosphatase
(Fig. 6). No positive staining above background was
observed in either the 3-mm-diameter defects or the 5-
mm-diameter defects irrespective of the FGF-2 treatment.
Thus the reparative tissue is substantially composed of
undifferentiated ﬁbroblastic cells in agreement with histo-
logical observations mentioned above. Then, we assessed
the packing cell density of the reparative tissue and the
proliferative capacity of the undifferentiated ﬁbroblastic cells
that had ﬁlled the defect cavities by immunostaining
PCNA11,12. We stained the sections of the femoral trochlearecovered at 1 and 2 weeks after creation of the defects
with hematoxylin and eosin, respectively. Then, semi-serial
sections were stained with PCNA antibody.
In the 3-mm-diameter defects, most of the undifferentiated
cells were positively stained with PCNA antibody at 1 week
[Fig. 7(A)]. At 2 weeks, the PCNA immunoreactivity
persisted widely in mesenchymal cells beneath the surfac-
ing area [Fig. 8(A)]. In the 5-mm-diameter defects without
the FGF-2 treatment, by contrast, PCNA-positive cells were
restricted only in the marginal areas of the defect cavities
both at 1 week and at 2 weeks [Figs. 7(C) and 8(C)]. Most
of the cells in the center of the defects did not express
PCNA immunoreactivity [Figs. 7(B) and 8(B)]. However,
administration of FGF-2 strikingly increased the PCNA
immunoreactivity in undifferentiated mesenchymal cells in
the 5-mm-diameter defects. Most of the undifferentiated
cells were evidently stained with PCNA antibody at 1 week
[Fig. 7(D)] and the immunoreactivity persisted in even at
2 weeks [Fig. 8(D)]. The pattern of immunostaining was
accorded well with that in the 3-mm-diameter defects.
PCNA immunoreactivity was barely detectable in chondro-
cytes of the pre-existing articular cartilage surrounding the
defects. Application of FGF-2 exerted no apparent effect on
proliferative activity in these chondrocytes (data not shown).
Table I summarizes the packing cell density and the
incidence of PCNA-positive cells in the reparative tissues.
At 1 week, along with the packing cell density, the incidence
of PCNA-positive cells for the whole defect and the packing
593Osteoarthritis and Cartilage Vol. 12, No. 7Fig. 7. Immunohistochemistry of PCNA in the reparative 3-mm-diameter defects treated with saline alone (A), 5-mm-diameter defects treated
with saline alone (B, C), and 5-mm-diameter defects treated with FGF-2 (D) at 1 week after creation of the defects. Panels A, B, and D
represent the PCNA-positive cells beneath the surfacing areas of the defects which correspond to the areas denoted by the asterisks in panels
A, B, and C in Fig. 2, respectively. Panel C represents the PCNA-positive cells in the peripheral area of the defects which corresponds to the
area denoted by the open circle in panel B of Fig. 2. The sections were counterstained with methyl green. Bar: 50 mm.cell density was signiﬁcantly lower in the 5-mm-diameter
defects than that in the 3-mm-diameter defects. The
incidence of PCNA-positive cells in the 5-mm-diameter
defects remained to a lower level even at 2 weeks in the 5-
mm-diameter defects. By contrast, the incidence of PCNA-
positive cells in the FGF-2-treated 5-mm-diameter defects
was as high as that in the 3-mm-diameter defects at 1 and 2
weeks, which was signiﬁcantly higher than that in the non-
treated 5-mm-diameter defects. The packing cell-density at
1 week was also signiﬁcantly higher in the FGF-2-treated
defects than that in the 5-mm-diameter defects without
FGF-2 treatment. In the 3-mm-diameter defects and the
FGF-2-treated 5-mm-diameter defects, no signiﬁcant differ-
ence was found in the incidence of PCNA-positive cells
between the peripheral and central region of the defects.
Interestingly, in the 5-mm-diameter defects without FGF-2
treatment, the incidence of PCNA-positive cells for the
peripheral region was 3- to 4-fold higher than that for the
central region.
Discussion
Regeneration of cartilage occurs in a defect-size de-
pendent manner during repair of full-thickness defect of
articular cartilage (Fig. 2)3,13. As demonstrated by immu-
nohistochemistry, regenerated cartilaginous tissue expres-
ses abundant cartilage-characteristic matrix components
(Figs. 3e5). In the 3-mm-diameter cylindrical defects,
cartilaginous tissue is spontaneously formed and theregenerated cartilage is then subsequently replaced by
the accretionary growth of subchondral bone up to the
original boneearticular cartilage junction. Thus the smaller
defects are covered with surfacing articular cartilage.
Although the accretionary growth of subchondral bone
occurs, no cartilage formation takes place in the 5-mm-
diameter larger defects. Local administration of FGF-2
within the defect cavities apparently overcomes this size-
limitation of cartilage repair. Treatment of 3-mm-diameter
defects with neutralizing anit-FGF-2 monoclonal antibody
markedly inhibited spontaneous cartilaginous repair to
occur3. As there was no evidence to indicate the pro-
liferation of pre-existing articular chondrocytes2,3, the
growth of pre-existing chondrocytes is not involved in the
actions of endogenous and/or exogenous FGF-2 during
repair of defects. Obviously, undifferentiated mesenchymal
progenitor cells that migrated from bone marrow were the
likely targets of the FGF-2 actions (Fig. 6).
Chondrogenic differentiation of mesenchymal cells pro-
ceeds through an ordered cascade of cellular events as
demonstrated in vivo and in vitro: (1) the mobilization and
migration of cells to the site of chondrogenesis, (2)
prechondrogenic cellular interactions and condensation,
and (3) the overt differentiation to chondrocytes4. Cellular
condensation is itself a multi-step process, which involves
initiation, establishment of boundary conditions, cell adhe-
sion, proliferation and growth. Although FGFs may act at
more than one stage in this cascade of events, it is
implicated that they play a central role in the active
proliferation of progenitor cells and the maintenance of the
594 H. Mizuta et al.: Cell Proliferation in Cartilage repairFig. 8. Immunohistochemistry of PCNA in the reparative 3-mm-diameter defects treated with saline alone (A), 5-mm-diameter defects treated
with saline alone (B, C), and 5-mm-diameter defects treated with FGF-2 (D) at 2 weeks after creation of the defects. Panels A, B, and D
represent the PCNA-positive cells beneath the surfacing areas of the defects which correspond to the areas denoted by asterisks in panels D,
E, and F in Fig. 2, respectively. Panel C represents the PCNA-positive cells in the peripheral area of the defects which corresponds to the area
denoted by the open circle in panel E of Fig. 2. The sections were counterstained with methyl green. Bar: 50 mm.progenitor cell population at the site of cartilage forma-
tion5,7,14,15. Tsutsumi and coworkers reported that FGF-2
potently stimulated self-renewal of mesenchymal stem cells
or mesenchymal progenitor cells without loss of differenti-
ation potentials16. In agreement with this notion and our
preliminary experiments8, the FGF-2 (50 pg/h for 2 weeks)
treatment of 5-mm-diameter defects resulted in the marked
increase of PCNA-positive undifferentiated cells prior to
overt chondrogenesis in the reparative tissue, as compared
to that in the untreated 5-mm-diameter defects (Table I).
Average incidence of PCNA-positive cells dramatically
increased by FGF-2 from 16.5% to 57.8% at 1 week after
creation of defects and from 19.4% to 40.1% at 2 weeks.
The increased level of PCNA-positive cells was comparable
to that of cells in the 3-mm-diameter smaller defects (56.1%
at 1 week and 42.9% at 2 weeks), where overt chondro-
genesis was spontaneously induced. The resultant carti-
laginous tissue occupied the defect cavities from 2 to 4
weeks after creation of defects2,3.
Thus, as indexed by a high incidence of PCNA-positive
cells, active expansion and maintenance of progenitor cell
populations were well correlated with the capacity of
subsequent overt chondrogenesis to occur (Figs. 7 and 8).
The 3-mm-diameter smaller defects were fully covered with
the proliferating cell population from the periphery of
subchondral bone to the center (Fig. 1). By the FGF-2
administration, the defect cavities were similarly covered
with the proliferating progenitor cell population (Figs. 7 and
8). Endogenous FGF-2 signaling is also implicated in
the spontaneous chondrogenic repair response in the
3-mm-diameter smaller defects, since a neutralizing mono-clonal antibody against FGF-2 completely blocked overt
chondrogenesis in these smaller defects3,8.
As trabecular bone surface is one of major storage sites
of FGF-2 in the body8,17, a ﬂux of FGF-2 liberated from
subchondral bone surface during creation of defects by
drilling and the initial hematoma formation can be a candi-
date of endogenous source of FGF-2. In addition, as
previously demonstrated by in situ hybridization and
immunohistochemistry, mesenchymal cells that strongly
express FGF-2 accumulated from the periphery of sub-
chondral bone in the defect cavities3. These cells can also
serve as a source of endogenous FGF-2 signaling.
The ﬂux of FGF-2 may be supplied in a manner
proportional to the surface area (square of a defect size)
of subchondral bone facing a defect cavity, while the
volume of a defect cavity increases with cubic of a defect
size. Thus it is reasonably assumed that the supply of
endogenous FGF-2 signaling cannot catch up with the
increasing demand of FGF-2 signaling required for the
maintenance of an expanding progenitor cell population in
larger defects. As shown in Table I, without administration
of exogenous FGF-2, a gradient of PCNA-positive cells
was formed in 5-mm-diameter defects. At the central
region [hatched area shown in Fig. 1(B, D)], the population
of proliferating cells must be reduced below a critical
threshold (4.8% at 1 week and 5.7% at 2 weeks) for
induction of overt chondrogenesis, as compared to that
(28.2% at 1 week and 31.0% at 2 weeks) in the peripheral
region of subchondral bone surface. Therefore, even
though cartilaginous induction took place occasionally
at the periphery of bone, regenerating cartilage failed to
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Cellularity and incidence of PCNA-positive cells in the reparative tissue in the defects
 3-mm diameter defect
Control 5-mm diameter defect
FGF-treated 5-mm diameter defect
58.4 ± 11.3
4.8 ±   3.8
58.7 ± 13.2
53.7 ± 16.1
28.2 ±  9.4
56.8 ± 17.9
PCNA-positive cells‡ (% of total)
Peripheral region
At 1 week
39.4 ± 10.5
5.7 ±   6.5
33.3 ± 21.8
46.3 ± 14.9
31.0 ±   6.2
46.9 ± 19.5
Cell density†
(cells x 10-3/µm2) Central region Whole defect
56.1 ± 13.4
16.5 ±   7.6
57.8 ± 15.7
42.9 ± 10.6
19.4 ±   6.3
40.1 ± 22.1
1.86 ± 0.38
0.66 ± 0.23
1.16 ± 0.44
1.93 ± 0.87
2.01 ± 0.20
3.51 ± 0.76
**
**
*
*
**
**
**
**
**
*
*
**
**
**
 3-mm diameter defect
Control 5-mm diameter defect
FGF-treated 5-mm diameter defect
At 2 week
Values are meansGSD for ﬁve animals. *P!0:05, **P!0:01.
yAll nuclei were counted in a total of 72 ﬁelds in the 3-mm-diameter defects at 1 week, 120 in the 5-mm-diameter defects at 1 week, 48 in the
3-mm-diameter defects at 2 weeks, and 96 in the 5-mm-diameter defects at 2 weeks using three sections for each animal at a magniﬁcation of
!200, as described in Materials and methods.
zThe PCNA-positive and -negative mesenchymal cells also were counted in a total of 180 ﬁelds in the 3-mm-diameter defects at 1 week, 300
in the 5-mm defects at 1 week, 120 in the 3-mm-diameter at 2 weeks, and 240 in the 5-mm-diameter defects at 2 weeks using three sections
for each animal at a magniﬁcation of !400.cover the entire surface of the 5-mm-diameter defect
cavities.
In the present study, we demonstrated that the successful
cartilaginous resurfacing of full-thickness defects required
the initiation and maintenance of expanding chondroproge-
nitor cell population prior to overt chondrogenesis in the
defect cavities. The data suggest that FGF-2 signaling plays
a role in this process as a regulatory mechanism for a
defect-size dependent regeneration of articular cartilage.
Further understanding of regulatory mechanism of cartilage
regeneration may provide clues for new therapeutic strat-
egy of regenerative medicine.
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